Document is current
Any future updates will be listed below
-
Authors
Basyreva, L. Yu.
Shmeleva, E. V.
Zubko, V. S.
Filatova, E. S.
Galkina, N. V.
Khoroshilova, Ya. B.
Rusakova, T. A.
Lazov, M. A.
Skopintsev, I. V.
Lvovsky, A. I.
Sivaev, A. A.
Gritskova, I. A.
Sokolov, A. V.
Gusev, S. A.
Chvalun, S. N.
Panasenko, O. M.
- License Information
-
More Information
Article History
Received: 15 October 2024
Revised: 26 November 2024
Accepted: 6 December 2024
First Online: 21 July 2025
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
: The clinical study was approved by the local ethics committee (protocol of the meeting of the ethics committee at the Lopukhin Federal Research and Clinical Center of Physical–Chemical Medicine of Federal Medical Biological Agency no. 2022/10/05 dated October 5, 2022) and was performed by taking blood samples from patients with T2DM (n = 12) and healthy volunteers (n = 6). Each participant in the study provided a voluntary written informed consent after receiving an explanation of the potential risks and benefits, as well as the nature of the upcoming study.
: The authors of this work declare that they have no conflicts of interest.
